Please use this identifier to cite or link to this item: https://hdl.handle.net/10356/142226
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheng, Hong Shengen_US
dc.contributor.authorTan, Wei Renen_US
dc.contributor.authorLow, Zun Siongen_US
dc.contributor.authorMarvalim, Charlieen_US
dc.contributor.authorLee, Justin Yin Haoen_US
dc.contributor.authorTan, Nguan Soonen_US
dc.date.accessioned2020-06-17T08:04:06Z-
dc.date.available2020-06-17T08:04:06Z-
dc.date.issued2019-
dc.identifier.citationCheng, H. S., Tan, W. R., Low, Z. S., Marvalim, C., Lee, J. Y. H., & Tan, N. S. (2019). Exploration and development of PPAR modulators in health and disease : an update of clinical evidence. International Journal of Molecular Sciences, 20(20), 5055-. doi:10.3390/ijms20205055en_US
dc.identifier.issn1661-6596en_US
dc.identifier.urihttps://hdl.handle.net/10356/142226-
dc.description.abstractPeroxisome proliferator-activated receptors (PPARs) are nuclear receptors that govern the expression of genes responsible for energy metabolism, cellular development, and differentiation. Their crucial biological roles dictate the significance of PPAR-targeting synthetic ligands in medical research and drug discovery. Clinical implications of PPAR agonists span across a wide range of health conditions, including metabolic diseases, chronic inflammatory diseases, infections, autoimmune diseases, neurological and psychiatric disorders, and malignancies. In this review we aim to consolidate existing clinical evidence of PPAR modulators, highlighting their clinical prospects and challenges. Findings from clinical trials revealed that different agonists of the same PPAR subtype could present different safety profiles and clinical outcomes in a disease-dependent manner. Pemafibrate, due to its high selectivity, is likely to replace other PPARα agonists for dyslipidemia and cardiovascular diseases. PPARγ agonist pioglitazone showed tremendous promises in many non-metabolic disorders like chronic kidney disease, depression, inflammation, and autoimmune diseases. The clinical niche of PPARβ/δ agonists is less well-explored. Interestingly, dual- or pan-PPAR agonists, namely chiglitazar, saroglitazar, elafibranor, and lanifibranor, are gaining momentum with their optimistic outcomes in many diseases including type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and primary biliary cholangitis. Notably, the preclinical and clinical development for PPAR antagonists remains unacceptably deficient. We anticipate the future design of better PPAR modulators with minimal off-target effects, high selectivity, superior bioavailability, and pharmacokinetics. This will open new possibilities for PPAR ligands in medicine.en_US
dc.language.isoenen_US
dc.relation.ispartofInternational Journal of Molecular Sciencesen_US
dc.rights© 2019 The Authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).en_US
dc.subjectScience::Medicineen_US
dc.titleExploration and development of PPAR modulators in health and disease : an update of clinical evidenceen_US
dc.typeJournal Articleen
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en_US
dc.identifier.doi10.3390/ijms20205055-
dc.description.versionPublished versionen_US
dc.identifier.pmid31614690-
dc.identifier.scopus2-s2.0-85073289222-
dc.identifier.issue20en_US
dc.identifier.volume20en_US
dc.subject.keywordsClinical Trialsen_US
dc.subject.keywordsMetabolic Syndromeen_US
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:SBS Journal Articles

SCOPUSTM   
Citations 10

23
Updated on Mar 10, 2021

PublonsTM
Citations 10

23
Updated on Mar 8, 2021

Page view(s)

25
Updated on Apr 15, 2021

Download(s) 50

23
Updated on Apr 15, 2021

Google ScholarTM

Check

Altmetric


Plumx

Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.